No Data
Shanghai RAAS Blood Products (002252.SZ): Haiyingkang has cumulatively increased its shareholding by 36.6187 million shares.
On April 8, Glonghui reported that Shanghai RAAS Blood Products (002252.SZ) announced that since the announcement of this Shareholding plan, the company's controlling Shareholder Haiyingkang has cumulatively increased its shareholdings by 36.6187 million shares through the Shenzhen Securities Exchange trading system using centralized bidding, accounting for 0.55% of the company's current total share capital (6,637,984,837 shares), with an investment amount of 253.0318 million yuan (excluding fees). As of now, Haiyingkang's Shareholding plan is still not completed. By April 7, 2025, Haiyingkang will hold 1,438,154,552 shares of Shanghai RAAS Blood Products.
Shanghai RAAS Blood Products (002252.SZ): The company has no recombinant Indicators for sale.
On April 8, Glonghui reported that Shanghai RAAS Blood Products (002252.SZ) stated on the investor interaction platform that in the first half of 2024, the revenue from its agency of Grifols albumin products was 1.955 billion yuan, accounting for 45.97% of the company's revenue for the same period, with a gross margin of 17.86%. The company will closely monitor changes in tariff policies and will adjust its procurement and supply strategies through collaboration between self-produced and imported products, allocations between various production locations of imported products, and other measures to minimize the impact. The company does not have recombinant coagulation factors for sale.
Shanghai RAAS Blood Products (002252.SZ): On April 2, 8.2999 million shares were repurchased for the first time.
On April 2, Gelonghui reported that Shanghai RAAS Blood Products (002252.SZ) announced that as of March 31, 2025, the company had not yet implemented a share buyback. On April 2, 2025, the company began its first share buyback through a dedicated securities account using a centralized bidding method, repurchasing a total of 8.29991 million shares, accounting for 0.13% of the company's total share capital. The highest Fill Price for the first buyback was 7.09 yuan/share, the lowest Fill Price was 7.02 yuan/share, and the total amount of the transaction was 58.55508 million yuan (excluding transaction commissions and other trading fees).
Express News | Shanghai Raas Blood Products Says It Plans to Buy Biopharmaceutical Company for 4.2 Bln Yuan
Shanghai RAAS Blood Products (002252.SZ) Shareholder has cumulatively increased the Shareholding of the company by 0.35%.
Shanghai RAAS Blood Products (002252.SZ) issued an announcement, stating that today it received a notice from its controlling shareholder Haiying Kang, informing that Haiying...
Gelonghui announcement highlights | GD Power Development: Plans to invest 4.508 billion yuan to construct the Dadu River Eagle Rock Level 1 Hydropower Station project; Tianhe Magnetic Material: No humanoid Siasun Robot&Automation related business at prese
【Hot Topic】EmbedWay Technologies (603496.SH): The company's Ascend Deepseek integrated machine is still in the prototype development and promotion stage. Foshan Golden Milky Way Intelligent Equipment (300619.SZ) recently engaged in deep cooperation with Microvast in the Solid State Battery field. Tianhe Magnetic Materials (603072.SH): There is currently no business related to humanoid robots. Shanghai Emperor of Cleaning Hi-Tech (603200.SH): The Solid State Battery related business has not yet obtained bulk Orders, and has not yet formed stable long-term revenue. Zhejiang Tengen Electrics (605066.SH): The revenue from products applied in the Industry of robots is less than 2 million yuan, accounting for a very small proportion.
